Liothyronine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hypothyroidism

• Levothyroxine

Other medications in Endocrine

• Methimazole
• Propylthiouracil
• Cholecalciferol
• Ergocalciferol

What Liothyronine is approved for (FDA label)

Liothyronine sodium is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. ( 1 ) 1.1 Hypothyroidism Liothyronine sodium is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 1.2 Pituitary Thyroid-Stimulating Hormone (TSH) Suppression Liothyronine sodium is indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer . 1.3 Thyroid Suppression Test Liothyronine sodium is indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Source: Read the full FDA label on DailyMed. Label effective date: June 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Liothyronine (FDA label)

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS • Thyroid hormones, including LIOTHYRONINE SODIUM, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. • Thyroid hormones, including liothyronine sodium, should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity ( 6 , 7.7 , 10 ).

Source: FDA prescribing information (DailyMed). Set ID: 115a84c2-0126-4dd7-816e-1873875f1e49. SPL document ID: 4f442ced-f23b-4005-95e2-4ce01636ac19. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Liothyronine (FDA label)

Tablets (round, white to off-white) available as follows: • 5 mcg: debossed with KPI on one side and 115 on the other side • 25 mcg: scored on one side and debossed with KPI and 116 on the other side • 50 mcg: scored on one side and debossed with KPI and 117 on the other side Tablets: 5 mcg, 25 mcg, 50 mcg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 115a84c2-0126-4dd7-816e-1873875f1e49. SPL document ID: 4f442ced-f23b-4005-95e2-4ce01636ac19. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Liothyronine (FDA label)

Adverse reactions associated with liothyronine sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5.4) and Overdosage (10) ] . They include the following: General : fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system : headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal : tremors, muscle weakness and cramps Cardiovascular : palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory : dyspnea Gastrointestinal : diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic : hair loss, flushing Endocrine : decreased bone mineral density Reproductive : menstrual irregularities, impaired fertility Most common adverse reactions for liothyronine sodium are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving thyroid replacement therapy.

Source: FDA prescribing information (DailyMed). Set ID: 115a84c2-0126-4dd7-816e-1873875f1e49. SPL document ID: 4f442ced-f23b-4005-95e2-4ce01636ac19. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Liothyronine (FDA label)

Liothyronine sodium is contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.3) ] . Uncorrected adrenal cortical insufficiency ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 115a84c2-0126-4dd7-816e-1873875f1e49. SPL document ID: 4f442ced-f23b-4005-95e2-4ce01636ac19. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Liothyronine (FDA label)

• Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate liothyronine sodium at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation ( 2.3 , 5.1 , 8.5 ) • Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma ( 5.2 ) • Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of liothyronine sodium treatment ( 5.3 ) • Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism ( 5.4 ) • Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements.

Source: FDA prescribing information (DailyMed). Set ID: 115a84c2-0126-4dd7-816e-1873875f1e49. SPL document ID: 4f442ced-f23b-4005-95e2-4ce01636ac19. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Liothyronine (FDA label)

See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to liothyronine sodium ( 7 ) 7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics (e.g. absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to liothyronine sodium (see Tables 1 – 4). Table 1: Drugs That May Decrease T3 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of liothyronine sodium by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Bile Acid Sequestrants -Colesevelam -Cholestyramine -Colestipol Ion Exchange Resins -Kayexalate -Sevelamer Bile acid sequestrants and ion exchange resins are known to decrease thyroid hormones absorption.

Source: FDA prescribing information (DailyMed). Set ID: 115a84c2-0126-4dd7-816e-1873875f1e49. SPL document ID: 4f442ced-f23b-4005-95e2-4ce01636ac19. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.